Which two intravitreal injections were compared in the CATT study?

The CATT study, which stands for Comparison of Age-Related Macular Degeneration Treatments Trials, specifically investigated the effectiveness of two anti-VEGF (vascular endothelial growth factor) agents—Ranibizumab and Bevacizumab—in the treatment of exudative age-related macular degeneration. This study was pivotal in assessing not only the visual outcomes associated with these treatments but also their safety profiles.

Ranibizumab is a humanized monoclonal antibody fragment that specifically inhibits VEGF, while Bevacizumab is a full-length monoclonal antibody that also targets VEGF but was initially developed for cancer treatment. The comparison in the CATT study helped establish that both medications could improve vision in patients with AMD, with insight into their relative efficacy, dosing regimens, and cost-effectiveness. This research has been influential in guiding treatment options for clinicians managing patients with this condition.

In contrast, the other combinations presented do not align with the focus of the CATT study. Aflibercept was not included in this specific comparison, and Faricimab is an even newer treatment that was not evaluated in the CATT trial.